Biologic

A biologic is a medication made from living cells or biological systems — cultured proteins, monoclonal antibodies, gene therapies — rather than synthesized chemically like traditional small-molecule drugs. The complexity of manufacturing means biologics can't be perfectly duplicated the way generics can; the closest equivalents are biosimilars, which must match the reference biologic in safety, purity, and potency but aren't identical at the molecular level.

Biologics have transformed treatment for autoimmune conditions (Humira, Enbrel, Remicade for rheumatoid arthritis and Crohn's), cancer (Herceptin, Rituxan, Keytruda), and many rare diseases. They also drive an enormous share of drug spend — a single biologic can cost $50,000 to $200,000 per patient per year. Manufacturing complexity, cold-chain logistics, and IV or injection administration make delivery more complex than a pill. Most biologics require prior authorization, are placed on specialty tiers with 20 to 40 percent coinsurance, and are dispensed only through specialty pharmacies. Biosimilar entry has slowly pulled prices down (Humira biosimilars entered the US market in 2023 after 20 years of brand exclusivity), though uptake has been slower than expected because of contract and rebate dynamics.

The takeaway: if a biologic is prescribed, ask three questions: is there a biosimilar available and on your formulary, is a manufacturer patient assistance program available, and is there a lower-cost site of care (home infusion, freestanding infusion center) than a hospital outpatient department. All three can materially reduce cost.